Every material Form 8-K NextPlat Corp has filed with the SEC since July 15, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
NextPlat Corp said it completed its previously announced acquisition of an independent pharmacy near Pensacola, Florida, for total cash consideration of $1,485,439. The pharmacy generated approximately $5.6 million in sales for the year ended December 31, 2025, and the company said it was profitable. The filing does not report the impact on NextPlat's consolidated results, so shareholders can see the deal size but not its effect on company earnings.
Total cash consideration for the pharmacy and its inventory was $1,485,439.
The pharmacy generated approximately $5.6 million in sales for the year ended December 31, 2025.
The pharmacy will be integrated into the PharmcoRx segment, which now operates five pharmacies in Florida.
The deal was announced in a press release dated October 6, 2026, filed as Exhibit 99.1.
NextPlat reported second-quarter 2026 revenue of $11.9 million, down from $13.2 million a year earlier but up 21% from the first quarter. The net loss narrowed to $144,000, or $0.05 per diluted share, from $1.8 million, or $0.69 per share, in the prior-year quarter. The company's gross margin of about 40% was a record, but the filing gives no revenue or earnings guidance figures.
Revenue was $11.9 million, down from $13.2 million a year earlier and up about 21% from $9.9 million in the first quarter of 2026.
Gross margin was about 40%, a record, compared with 22% in the second quarter of 2025.
Net loss attributable to common stockholders was $144,000, or $0.05 per diluted share, versus $1.8 million, or $0.69 per share, a year earlier; the company cites about $0.5 million in one-time professional fees.
Cash was $11.9 million at June 30, 2026, with no material unsecured debt; the company also announced an intended acquisition of a pharmacy operation in the Pensacola area.
NextPlat's indirect subsidiary Progressive Care, LLC agreed on July 14, 2026 to acquire 100% of Scott's Pharmacy, LLC, a community pharmacy in Molino, Florida, for $1.5 million in cash, subject to an inventory adjustment. The filing says the pharmacy generated about $5.6 million in sales in 2025, and the deal is expected to expand NextPlat's PharmcoRx retail and contracted-services footprint in the panhandle region, though closing is not yet complete.
Purchase price is $1,500,000 in cash, with a $50,000 initial escrow deposit credited at closing and $50,000 held in escrow for indemnification for 18 months after closing.
Closing is targeted by September 30, 2026, with a one-time extension to October 31, 2026, available upon notice and an additional $50,000 deposit.
The Company has a 30-day due diligence period and must negotiate a lease for the premises; failure to do so allows termination without penalty.
Per the press release, the pharmacy had approximately $5.6 million in 2025 sales and retail margins of about 19%, and NextPlat's 2025 annual revenue was $54.3 million.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every NextPlat Corp filing is on SEC EDGAR ↗. 8-K briefs of other companies →